SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ggamer who wrote (329)10/2/2007 2:50:51 PM
From: Keith FeralRead Replies (1) of 418
 
Those comments sum up the FUD pretty well.

I think the key to the phase 3 is the higher toxicity from bolus 5FU and Avastin daily regimen. Cofactor will have a greater opportunity for toxicity reduction due to the presence of different cytotoxic drugs. Ideally, bolus 5FU and Cofactor would be achieve the higher response rates seen in earlier bolus 5FU Cofactor trials, along with an elimination of side effects from the 5FU and Avastin in the daily regimen.

They need to get with their marketing partners now and finally pull the deal together.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News